NovoCure Limited (NVCR) Operating income 2017–2026
NovoCure Limited (NVCR) annual operating income history from SEC filings — each fiscal year as reported.
-$153.8MFY2026 · since FY2017: -$115.3M → -$153.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$153.8M | +9.8% |
| FY2025 | -$170.5M | +26.8% |
| FY2024 | -$232.9M | -160.1% |
| FY2023 | -$89.5M | -101.9% |
| FY2022 | -$44.3M | -245.8% |
| FY2021 | $30.4M | +3426.1% |
| FY2020 | -$914,000 | +97.3% |
| FY2019 | -$33.7M | +14.4% |
| FY2018 | -$39.3M | +65.9% |
| FY2017 | -$115.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NVCR financial trends
NVCR RevenueNVCR Net incomeNVCR Net marginNVCR Gross profitNVCR Gross marginNVCR Operating marginNVCR Operating cash flowNVCR Free cash flowNVCR Capital expendituresNVCR Return on equityNVCR Stock buybacksNVCR Dividends paidNVCR Total assetsNVCR Total liabilitiesNVCR Shareholders’ equityNVCR overview →